Switch to:
More From Other Websites
EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Sep 26 2016
4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate Sep 26 2016
Surging Earnings Estimates Signal Good News for Exelixis (EXEL) Sep 26 2016
Exelixis Elects Julie Anne Smith to Its Board of Directors Sep 26 2016
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for... Sep 26 2016
6:11 am Exelixis announces its partner Daiichi Sankyo (DSNKY)... Sep 26 2016
Exelixis Elects Julie Anne Smith to Its Board of Directors Sep 26 2016
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for... Sep 26 2016
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for... Sep 26 2016
Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016... Sep 20 2016
3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL) Sep 20 2016
Will Exelixis (EXEL) Continue to Surge Higher? Sep 15 2016
Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL) Sep 14 2016
Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar Sep 14 2016
Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar Sep 14 2016
Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug Sep 14 2016
4 stocks to watch Sep 14 2016
Key FDA Decisions and Trial Results Coming in the Next 2 Months Sep 14 2016
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal... Sep 14 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK